Jan 09,2023

ConcertAI and Caris Life Sciences Form Broad Partnership Creating Industry-Leading Molecular Oncology Research Platform to Accelerate Drug Development and Novel Research

ConcertAI and and Caris Life Sciences®(Caris), the leading molecular science, artificial intelligence (AI) and machine learning technology company announced a unique partnership to align the two companies' oncology capabilities. The collaboration creates one of the largest translational and clinical development research platforms aimed at supporting and accelerating biopharmaceutical drug development and novel therapeutic research. While detailed partnership terms have not been disclosed, as part of the partnership, the two organizations will also align their scientific talent and AI SaaS technologies to the research objectives of their academic and biopharma partners.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Nov 25,2022

EU launches AI-powered real-world data project for cancer therapies

The European Commission has provided around €7 million ($7.2 million) in funding to a new project that aims to boost the ability of hospitals within the EU to collect real-world data (RWD). Dubbed ONCOVALUE, the initiative will set up a consortium that will develop an artificial intelligence (AI) platform that will be used for routine collection and analysis of clinical data on new oncology medicines to support their assessment by regulators and health technology assessment (HTA) agencies. It is being led by Helsinki University Hospital (HUS), with Swiss data specialist BC Platforms selected as one of the technology partners for the project.

#rwd

View Analyst & Ambassador Comments
Go to original news
Dec 03,2020

Syneos Health and ConcertAI Announce Strategic Collaboration to Accelerate the Use of Real World Evidence and AI to Advance Oncology Research

Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization and ConcertAI, the leader in oncology real world evidence (RWE) and patient outcomes solutions for the biopharmaceutical and healthcare industries, today announced a strategic collaboration to accelerate and streamline the implementation of novel oncology clinical trial research and study designs. In a first-of-its kind CRO collaboration, ConcertAI will bring its deep experience in RWE generation, innovative RWE technologies and regulatory-grade oncology and urology real world data (RWD).

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

#rwd

View Analyst & Ambassador Comments
Go to original news
Dec 07,2021

Labcorp forges latest AI deal, partnering with ConcertAI for cancer studies

Labcorp has teamed with ConcertAI to use the latter’s technology to optimize clinical trials of candidate cancer drug therapies. The partnership – financial terms of which were not disclosed – will see Labcorp use artificial intelligence software to aid clinical trial design, protocol optimization, site selection and study execution activities. The firms will also incorporate real-world data into the optimization process. The plan to analyze patient availability at cancer centers worldwide to ensure that the design of a trial contains a diverse set of participants to measure drug safety and effectiveness in broadly representative populations.

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

#rwd

View Analyst & Ambassador Comments
Go to original news
Sep 29,2022

Real-World Data Collab Aims to Improve Diversity in Cancer Clinical Trials

The National Cancer Institute Community Oncology Research Program (NCI NCORP)-designated Louisiana State University (LSU) Health New Orleans is collaborating with artificial intelligence (AI) and real-world data solutions company ConcertAI to improve diversity in clinical trials and ensure broader access for cancer patients. The collaboration is part of ongoing work by LSU Health New Orleans and NCI NCORP to establish and improve the clinical trials network in the Gulf South region. According to the press release, NCI awarded LSU Health New Orleans a $5.6 million grant to create the network and another $13.6 million to expand it, with an emphasis on reaching underserved and minority patients. The collaboration also aligns with ConcertAI’s ERACE (Engaging Research to Achieve Cancer Care Equality) program. "The collaboration will identify current cancer care disparities in Louisiana and how they can be addressed," said Augusto Ochoa, MD, an LSU Health New Orleans NCORP principal investigator, in the press release. 

COLLABORATION PARTNERSHIP

#institution

#rwd

View Analyst & Ambassador Comments
Go to original news
Oct 04,2021

GNS Healthcare Announces a Multi-Year Collaboration with a Leading US Cancer Center to Advance Precision Medicine in Oncology

GNS Healthcare (GNS), an artificial intelligence company creating in silico patients that simulate drug treatment at the individual patient level, today announced a multi-year collaboration with Memorial Sloan Kettering Cancer Center (MSK) to leverage longitudinal multi-modal prostate cancer patient data and world class prostate cancer expertise with GNS’ Gemini in silico Prostate Cancer patient. This collaboration will address key questions for prostate cancer patients, including identifying subtypes of aggressive disease and discovering novel drug targets and drivers of patient response to an increasing array of therapeutics. These insights will enable the design of highly sophisticated clinical trials and generate evidence of comparative effectiveness between drugs and simulate treatment sequencing. The work will build on the existing Gemini – The in silico Patient™ for Prostate Cancer developed in partnership with Tempus. 

COLLABORATION PARTNERSHIP

#r&d

#rwd

View Analyst & Ambassador Comments
Go to original news
Aug 30,2022

Syapse and Genesis Research Form RWE Partnership in Oncology

Today, Syapse, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases, announced that they have entered into a strategic partnership with Genesis Research. As part of the partnership, Genesis Research will leverage Syapse’s leading real-world evidence platform, enabling the two companies to develop a deeper understanding of the challenges associated with complex cancers. Together, this relationship will enable Syapse to provide its clients access to Genesis’ integrated research partnerships.  

COLLABORATION PARTNERSHIP

#product & service

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Jun 14,2022

Pierian and Syapse Collaborate with Health Systems, Leveraging Data to Power Precision Oncology

Pierian®, a global leader in advanced clinical genomics technology and services, announced with Syapse®, a leading real-world evidence company, a new joint collaboration that will benefit patients of the AdventHealth Cancer Institute in Central Florida. The collaboration combines Pierian’s leading-edge clinical genomics workflow, and precision medicine services with Syapse’s real-world evidence solutions designed to improve outcomes for patients with cancer. Pierian and Syapse will collaborate on optimizing AdventHealth’s internal genomic testing capabilities for all patients who may benefit to improve the actionable insights gathered from test orders and genomic results allowing a deeper understanding of the relationship between these insights and real patient outcomes.

COLLABORATION PARTNERSHIP

#r&d

#rwd

#cdx

View Analyst & Ambassador Comments
Go to original news
Sep 17,2022

Science 37 and Syapse Partner to Enable Faster Patient Enrollment in Oncology Clinical Trials

Science 37 Holdings, Inc., the Agile Clinical Trial Operating System™, and Syapse, a leading real-world evidence company, today announced a partnership to deploy proprietary real-world data intelligence and analytics that will help identify suitable patients for oncology clinical trials—ultimately speeding up the enrollment process. Study sponsors are increasingly looking outside of traditional academic sites to source specific patient populations, but without the data to pinpoint patients’ locations, recruitment can be extremely challenging. To facilitate enrollment and reduce patient burden, oncology research executives have begun to rely more on agile (hybrid) and fully decentralized models. The partnership between the companies will enable the Oncology patients and clinical research sponsors to benefit from Syapse’s real-world data intelligence and Science 37’s agile trial operating system, to help accelerate the identification and participation of eligible participants.

COLLABORATION PARTNERSHIP

#product & service

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 05,2022

Illumina, Syapse Partner on Study of Comprehensive Genomic Profiling in Advanced Cancer

Syapse said on Tuesday that it has partnered with Illumina to assess uptake and actionability of comprehensive genomic profiling in the community oncology health system setting. The firms will evaluate single-gene, small panel, and comprehensive genomic profiling tests in advanced cancer patients. A focus of the study, which will use data from the Syapse Learning Health Network, the firm's data aggregation platform, will be trends in testing approaches over time and actionability of results. Syapse will conduct the analysis with input from Illumina. Financial and other terms of the deal were not disclosed. Upon completion of the analysis, the firms hope to present their results at a conference and publish them in a peer-reviewed journal, Syapse said.

COLLABORATION PARTNERSHIP

#r&d

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to RWD